Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration
Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective e...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2024-01-01
|
| Seria: | Life |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/2075-1729/14/2/193 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|